What is Invega Sustenna used to treat?

Paliperidone extended-release injections (Invega Sustenna, Invega Trinza) are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions).

What does invega do to the brain?

Invega works by restoring the balance of certain neurotransmitters in the brain. Invega impacts dopamine and serotonin in the brain. It works similarly and is chemically related to Risperdal, but often with fewer extrapyramidal side effects (such as tremor or stiffness).

Who manufactures Invega Sustenna?

Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved under priority review the New Drug Application (NDA) for the three-month long-acting atypical antipsychotic INVEGA TRINZA™.

How do you administer paliperidone depot?

Slowly inject the entire contents of the syringe intramuscularly, deep into the selected deltoid or gluteal muscle. Do not administer by any other route. After the injection is complete, use your thumb or a flat surface to secure the needle in the safety device.


INVEGA TRINZA® and INVEGA SUSTENNA® can cause serious side effects, including an increased risk of death in elderly people who are confused, have memory loss, and have lost touch with reality (dementia-related psychosis). INVEGA TRINZA® and INVEGA SUSTENNA® are not for treating dementia-related psychosis.

Where should INVEGA SUSTENNA be injected?

Inject slowly, deep into the deltoid or gluteal muscle. INVEGA SUSTENNA® must be administered using only the needles that are provided in the INVEGA SUSTENNA® kit.

Can INVEGA SUSTENNA be used for bipolar?

Summary. INVEGA SUSTENNA has not been studied and is not approved for use in patients with Bipolar Disorder.

Where should Invega Sustenna be injected?

Does Invega cause brain damage?

Cerebrovascular problems (stroke) that can lead to death have been reported in elderly patients with dementia-related psychosis. Neuroleptic Malignant Syndrome (NMS) is a rare but very serious problem that can happen in people who receive INVEGA ®. NMS can cause death and must be treated in a hospital.

When to discard syringe after Invega Sustenna injection?

After the injection is complete, use either thumb or finger of one hand (A, B) or a flat surface (C) to activate the needle protection system. The needle protection system is fully activated when a “click” is heard. Discard the syringe with needle appropriately. 1

When to start Invega Sustenna in the deltoid muscle?

The initiation regimen for INVEGA SUSTENNA® (234 mg/156 mg in the deltoid muscle on Day 1/Day 8) was designed to rapidly attain steady-state paliperidone concentrations when initiating therapy without the use of oral supplementation1 Select the appropriate needle size depending on the patient’s weight and injection location

What is the conversion factor for Invega Sustenna?

The conversion factor from mg eq. to mg is 1.56. INVEGA SUSTENNA doses expressed as 25, 50, 75, 100, and 150 mg eq. are equal to 39, 78, 117, 156, and 234 mg of paliperidone palmitate, respectively. Switching from oral RISPeridone